갑상선 안병증 치료 시장 : 치료법별, 투여 경로별, 유형별, 진단법별, 최종 사용자별, 유통 채널별 시장 예측(2026-2032년)

The Thyroid Eye Disease Treatments Market is projected to grow by USD 4.29 billion at a CAGR of 6.14% by 2032.

Thyroid eye disease (TED), also known as Graves' orbitopathy, is an autoimmune inflammatory disorder that affects the orbit and can cause proptosis, diplopia, eyelid retraction, pain, exposure keratopathy, and vision-threatening optic neuropathy. The condition is strongly associated with Graves' disease, although it can also occur in euthyroid or hypothyroid patients, making coordinated endocrine and ophthalmic care essential.

The thyroid eye disease treatments landscape has moved beyond symptom control toward targeted immunomodulation, earlier diagnosis, and staged surgical rehabilitation. Evidence-based care now combines risk-factor management, lubrication, selenium in selected mild cases, intravenous glucocorticoids for active moderate-to-severe disease in many guideline pathways, orbital radiotherapy for selected patients, IGF-1R pathway inhibition where approved and accessible, and decompression, strabismus, or eyelid surgery when disease becomes inactive.

Transformative Shifts in the Thyroid Eye Disease Treatment Landscape

The most important shift in thyroid eye disease treatment is the transition from reactive management to disease-modifying intervention. The U.S. FDA approval in 2020 of the first medicine specifically indicated for TED, an insulin-like growth factor-1 receptor inhibitor, changed clinical expectations for proptosis and diplopia outcomes in appropriate patients and intensified interest in targeted biologic therapy.

Clinical pathways are also becoming more multidisciplinary. Endocrinologists, oculoplastic surgeons, neuro-ophthalmologists, radiologists, and infusion providers are increasingly aligned around activity scoring, severity grading, thyroid stabilization, smoking cessation, and patient-reported outcomes. This shift supports earlier escalation for active disease while preserving the role of surgery for stable, fibrotic, or rehabilitative phases.

Cumulative Impact of Artificial Intelligence on TED Care

Artificial intelligence is beginning to create cumulative value across the thyroid eye disease treatments ecosystem by improving screening, severity assessment, and follow-up consistency. AI-supported image analysis of external photographs, CT, MRI, and optical measurements can help quantify proptosis, eyelid aperture, extraocular muscle enlargement, and orbital crowding, reducing interobserver variability in TED assessment.

In clinical operations, AI can support referral triage, predict flare risk using structured clinical data, and identify patients who may require urgent evaluation for compressive optic neuropathy. In drug development and evidence generation, machine learning can accelerate biomarker discovery, patient stratification, and real-world evidence analysis for biologics, corticosteroid-sparing regimens, and combination strategies, while governance remains critical for privacy, bias control, explainability, and clinical validation.

Key Regional Insights for Thyroid Eye Disease Treatments

In North America, thyroid eye disease treatment adoption is shaped by specialty centers, payer policies, infusion capacity, and access to the first FDA-approved TED-specific therapy in the United States, while Canada emphasizes specialist-led pathways and public-private reimbursement assessment. Europe follows strong guideline-driven practice, with expert consensus supporting structured activity and severity grading, intravenous glucocorticoids for many active moderate-to-severe cases, risk-factor modification, and rehabilitative surgery in inactive disease.

Asia-Pacific shows rising demand as China, Japan, India, South Korea, and Australia expand endocrine and ophthalmology capacity; however, access to biologics varies widely and cost containment remains significant. Latin America, including Brazil and Mexico, is advancing through private specialty networks and improving diagnostic awareness, though access to high-cost biologic therapy can be uneven. The Middle East benefits from tertiary hospitals in GCC markets that can support advanced imaging, infusion therapy, and orbital surgery, while Africa remains focused on specialist access, earlier diagnosis, thyroid control, smoking cessation, corneal protection, and prevention of severe ocular complications.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, thyroid eye disease treatment development is linked to expanding urban ophthalmology networks, teleophthalmology, and increasing recognition of Graves' disease complications, although affordability influences treatment sequencing. The GCC benefits from investment in tertiary care, cross-border medical services, and high-capability imaging and infusion infrastructure, supporting adoption of advanced TED management in major centers.

The European Union is characterized by guideline alignment, pharmacovigilance, cross-country health technology assessment, and structured reimbursement review, while BRICS countries combine large patient pools with uneven biologic access and strong demand for scalable diagnostics. G7 markets are central to clinical research, regulatory evaluation, real-world evidence generation, and advanced therapy uptake. NATO members overlap substantially with high-income health systems in North America and Europe, where coordinated specialty care and hospital-based infusion models support complex TED treatment delivery.

Key Country Insights for Thyroid Eye Disease Treatment Adoption

The United States remains the most advanced adoption environment for thyroid eye disease treatments due to early availability of a TED-specific biologic, high specialty awareness, and active real-world evidence generation. Canada, the United Kingdom, Germany, France, Italy, and Spain rely on specialist-led assessment and reimbursement review, with European practice maintaining strong adherence to structured staging, clinical activity scoring, and glucocorticoid protocols. Mexico and Brazil show improving access through private networks and tertiary centers, but high-cost therapy coverage remains a key determinant.

China and India represent large clinical need bases because of population size, Graves' disease burden, and expanding specialty care, while Japan, South Korea, and Australia combine high clinical standards with careful health technology assessment and strong imaging capabilities. Russia continues to rely heavily on established medical and surgical approaches. Across all countries, smoking cessation, thyroid normalization, early referral, lubrication, diplopia assessment, and protection of corneal and optic nerve function remain foundational to outcomes.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that compares real-world outcomes across IGF-1R inhibition, intravenous glucocorticoids, orbital radiotherapy, surgical rehabilitation, and emerging biologics or corticosteroid-sparing regimens. Patient registries, standardized clinical activity scoring, imaging-based severity assessment, and patient-reported outcome measures can strengthen reimbursement submissions and differentiate products or services in a field where functional and quality-of-life benefits are central.

Organizations should also invest in integrated care models connecting endocrinology, ophthalmology, imaging, infusion, and surgery. Commercial and clinical success will depend on educating clinicians about early referral, supporting payer discussions with health-economic evidence, developing access programs for high-cost therapies, improving adherence monitoring, and deploying AI tools only after rigorous validation in diverse patient populations.

Research Methodology

This executive summary is based on a structured secondary research approach using peer-reviewed ophthalmology and endocrinology literature, regulatory information from agencies such as the U.S. FDA and European authorities, clinical guidance from recognized expert groups, and publicly available evidence on approved and established thyroid eye disease treatments.

Insights were synthesized through triangulation of clinical guidelines, drug labels, real-world practice patterns, epidemiology literature, pharmacovigilance sources, and regional healthcare access indicators. The analysis emphasizes verified treatment pathways, clinical adoption factors, and observable industry drivers rather than unsupported estimates, ensuring that conclusions remain evidence-based, SEO-relevant, and suitable for executive decision-making.

Conclusion

The thyroid eye disease treatments landscape is entering a more targeted and multidisciplinary phase. Biologic therapy has raised expectations for active disease management, while corticosteroids, local supportive care, radiotherapy, thyroid control, and surgery continue to play essential roles across severity levels and disease phases.

Future progress will be shaped by earlier diagnosis, reimbursement decisions, real-world evidence, AI-enabled assessment, and the ability of health systems to coordinate complex care. Organizations that combine clinical rigor, patient access strategies, validated digital tools, and multidisciplinary treatment pathways will be best positioned in the evolving TED treatment landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Thyroid Eye Disease Treatments Market, by Treatment Type

• 7.1. Medical Treatment
  • 7.1.1. Corticosteroids
  • 7.1.2. Immunosuppressants
  • 7.1.3. Monoclonal Antibodies
  • 7.1.4. Thyroid Hormone Control
  • 7.1.5. Tyrosine Kinase Inhibitors
• 7.2. Surgical Treatment
  • 7.2.1. Eyelid Surgery
  • 7.2.2. Orbital Decompression Surgery
  • 7.2.3. Strabismus Surgery

8. Thyroid Eye Disease Treatments Market, by Route of Administration

• 8.1. Intravenous
• 8.2. Oral
• 8.3. Topical

9. Thyroid Eye Disease Treatments Market, by Type

• 9.1. Type I TED
• 9.2. Type II TED

10. Thyroid Eye Disease Treatments Market, by Diagnosis

• 10.1. Blood Test
• 10.2. Imaging Test
• 10.3. Orbital Ultrasound
• 10.4. Radioactive Iodine Uptake Test

11. Thyroid Eye Disease Treatments Market, by End-User

• 11.1. Hospitals
• 11.2. Outpatient Centers
• 11.3. Specialty Clinics

12. Thyroid Eye Disease Treatments Market, by Distribution Channel

• 12.1. Offline Retail
• 12.2. Online Retail

13. Thyroid Eye Disease Treatments Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Thyroid Eye Disease Treatments Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Thyroid Eye Disease Treatments Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. AbbVie, Inc
• 17.3. Allergan plc
• 17.4. Amgen
• 17.5. Bausch & Lomb Inc
• 17.6. Clearside Biomedical Inc
• 17.7. Eyevance Pharmaceuticals LLC
• 17.8. Hoffmann La Roche
• 17.9. Horizon Therapeutics plc
• 17.10. Immunovant, Inc.
• 17.11. Mabxience Research Sl
• 17.12. Merck & Co., Inc
• 17.13. Mylan N.V.
• 17.14. Novartis AG
• 17.15. Pfizer Inc
• 17.16. Sanofi